Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed solid malignancy that is metastatic or unresectable for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective.
Subjects with brain metastases must have clinically controlled neurologic symptoms.
Subject is able to swallow and retain oral medications and does not have uncontrolled emesis.
Subject has adequate bone marrow, renal and hepatic function per local laboratory reference ranges.
You may not be if
Uncorrected serum potassium, serum magnesium, serum calcium or free thyroxin (FT4) and thyroid stimulating hormone (TSH) outside of normal reference ranges, or grade 2 hyponatremia or hypernatremia.
Subject has severe ECG morphologic abnormalities that make QTc evaluation difficult.
Subject has a history of cardiac conduction abnormalities.
Subject has a significant history of cardiovascular disease.
Subject has received any anti-cancer therapies 21 days prior to the first dose of study drug, or has recovered to no better than a grade 2 or higher clinically significant adverse effect(s)/toxicity(s) of the previous therapy.
Use of drugs with a known risk for QT prolongation and Torsades de Pointes within 7 days prior to the first study dose.
Use of tobacco or nicotine-containing products within 12 hours prior to the first study dose.
Clareo Health | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
